Al Ashi Amro K, Meray Victorien, Aziz Adnan M
Translational Research Department, Herbert Wertheim College of Medicine, Florida International University, Miami, USA.
Internal Medicine, Jackson Health System, Miami, USA.
Cureus. 2022 Apr 11;14(4):e24033. doi: 10.7759/cureus.24033. eCollection 2022 Apr.
Balo concentric sclerosis (BCS) is a rare sub-variant of multiple sclerosis (MS), a demyelinating disease affecting the CNS. BCS is considered a disease of the brain's white matter with a characteristic tumefactive ring signified with alternating myelinated and demyelinated layers, which gives it an "onion-ring" appearance. Our patient is a 40-year-old male with a past medical history (PMH) of human papillomavirus (HPV) who presented to the hospital with acute onset of progressive horizontal diplopia in the left eye and mild right-sided facial weakness and sensation of heaviness in the head. After ruling out stroke, the patient's clinical presentation prompted further investigation with MRI, MR spectroscopy, and an oligoclonal bands' panel. MRI imaging showed a concentric bullseye area of T1 low signal intensity in the left parietal lobe with surrounding edema vasogenic ring enhancement. MR spectroscopy showed a sequence of incomplete ring-enhancing lesions demonstrating a lactate peak and increased choline. The oligoclonal bands' panel, which revealed negative oligoclonal bands, had elevated IgG in the CSF. The patient was diagnosed with BCS based on the clinical presentation, MRI, MR spectroscopy, and oligoclonal bands' panel findings. The patient was started on high doses of methylprednisolone, which improved his symptoms within 24-48 hours of the initial dose.
巴洛同心圆性硬化(BCS)是多发性硬化(MS)的一种罕见亚型,MS是一种影响中枢神经系统的脱髓鞘疾病。BCS被认为是一种脑白质疾病,具有特征性的肿胀环,表现为髓鞘化和脱髓鞘层交替出现,使其呈现出“洋葱环”外观。我们的患者是一名40岁男性,既往有人类乳头瘤病毒(HPV)病史,因左眼急性发作进行性水平性复视、轻度右侧面部无力和头部沉重感入院。排除中风后,患者的临床表现促使进一步进行MRI、磁共振波谱和寡克隆带检测。MRI成像显示左顶叶有一个T1低信号强度的同心靶心区域,周围有血管源性水肿环增强。磁共振波谱显示一系列不完全环形强化病变,显示乳酸峰和胆碱增加。寡克隆带检测显示寡克隆带阴性,但脑脊液中IgG升高。根据临床表现、MRI、磁共振波谱和寡克隆带检测结果,该患者被诊断为BCS。患者开始接受大剂量甲基泼尼松龙治疗,初始剂量后24至48小时内症状有所改善。